Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer
Extranodal extension (ENE) refers to the spread of head and neck squamous cell carcinoma
(HNSCC) outside the lymph nodes. It is a well-known factor that indicates a poorer prognosis
and outcome for patients who have undergone surgical removal of the cancer. In such ...
Age: 18 years - 66+
Gender: All
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
This study is a substudy being conducted under one pembrolizumab umbrella master study
KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and
safety of coformulated favezelimab/pembrolizumab plus EV and coformulated
vibostolimab/...
Age: 18 years - 66+
Gender: All
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of
danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line
treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients...
Age: 18 years - 66+
Gender: All
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced
non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due
to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radi...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as
monotherapy or in combination with ultralow dose gemcitabine in participants with
platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma
ba...
Age: 18 years - 66+
Gender: All
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
The primary purpose of this study is to determine the safety and tolerability of the
combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2
dose (RP2D) when administered as first line (1L) treatment in participants with locally...
Age: 18 years - 66+
Gender: All
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in
patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to
other places in the body (metastatic), or cannot be removed by surgery (unresectable).
...
Age: 18 years - 66+
Gender: All
Pembrolizumab in MIBC
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing
schedules of cemiplimab given in combination with cisplatin and docetaxel induction
chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head ...
Age: 18 years - 66+
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 ...
Age: 18 years - 66+
Gender: All
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or
Metastatic Solid Tumors
Age: 18 years - 66+
Gender: All
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual
chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2
p...
Age: 18 years - 66+
Gender: Female
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for
the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body
(advanced) or are not able to be removed by surgery (unresectable). Chemotherapy ...
Age: 18 years - 66+
Gender: All
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482)
plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the
adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
...
Age: 18 years - 66+
Gender: All
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK),
and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with
platinum-resistant ovarian cancer.
Age: 18 years - 66+
Gender: Female
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or
unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy
(Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x...
Age: 18 - 99 years
Gender: All
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386
in combination with pembrolizumab in participants with previously treated selected solid
tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination ...
Age: 18 years - 66+
Gender: All
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver
for hepatocellular cancer (HCC) detection in a surveillance population.
Age: 18 years - 66+
Gender: All